Physician profile
Laura Gandy
NPI 1427378306
$4,872.95
in general payments reported to CMS, 2019-2025
49 companies · $690 in 2025
The $690 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $238 · 2021: $316 · 2022: $600 · 2023: $931 · 2024: $1,157 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $577.88 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $485.47 | 2019-2025 | |
| Novo Nordisk INC | $350.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $319.53 | 2019-2025 | |
| Corcept Therapeutics | $237.69 | 2019-2024 | Korlym |
| Abbott Laboratories | $192.17 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $180.24 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $166.97 | 2019 | |
| Amgen INC. | $159.52 | 2019-2025 | Amjevita, Evenity, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.44 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Ibsa Pharma INC. | $126.09 | 2019-2024 | Tirosint, Licart, Tirosint |
| Astellas Pharma US INC | $122.98 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $112.50 | 2019-2024 | Dificid, Steglatro, Belsomra |
| Ucb, INC. | $111.98 | 2025 | Zilbrysq, Rystiggo |
| Ascendis Pharma Endocrinology INC | $106.29 | 2023-2025 | Yorvipath |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $104.83 | 2019-2024 | Tymlos |
| Dynavax Technologies Corporation | $96.10 | 2019-2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $87.22 | 2019-2024 | |
| Pfizer INC. | $82.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.39 | 2019-2025 | Airsupra |
| Beta Bionics, INC. | $77.30 | 2023-2024 | Ilet Bionic Pancreas |
| Gilead Sciences, INC. | $76.70 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $73.24 | 2019-2024 | Unithroid |
| Glaxosmithkline, LLC. | $62.85 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Sequel Med Tech, LLC | $59.02 | 2025 | Twiist |
| Mannkind Corporation | $55.86 | 2019-2022 | |
| Exact Sciences Corporation | $54.81 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $54.54 | 2022-2024 | Dexcom G6 Transmitter |
| Biogen, INC. | $53.51 | 2022-2025 | Leqembi |
| Horizon Therapeutics Plc | $41.78 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $40.72 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.06 | 2023-2024 | Xifaxan, Cycloset, Trulance |
| Acadia Pharmaceuticals INC | $30.69 | 2024-2025 | Nuplazid |
| Viiv Healthcare Company | $28.64 | 2022 | |
| Recordati_rare_diseases_inc. | $27.53 | 2022-2024 | Isturisa, Signifor Lar |
| Csl Behring | $24.95 | 2025 | Hizentra |
| Ultragenyx Pharmaceutical INC. | $24.76 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $24.58 | 2024 | Uptravi, Opsumit |
| Bigfoot Biomedical INC | $24.38 | 2023 | Unity Diabetes Management System |
| Medtronic Minimed, INC. | $17.38 | 2019 | |
| Shire North American Group INC | $16.37 | 2019 | |
| Cequr Corporation | $16.03 | 2023 | Cequr Simplicity |
| Aegerion Pharmaceuticals, INC. | $15.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.97 | 2019 | |
| Eusa Pharma (US) LLC | $13.38 | 2022 | |
| Valeritas, INC. | $13.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.66 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.02 | 2019 | |
| Vivus LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Gandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.